Viatris Inc. (VTRS)

11,57 -0,21 (-1,78 %) À la clôture : 04:00PM EDT

Viatris Inc.

1000 Mylan Boulevard
Canonsburg, PA 15317
United States
724 514 1800
https://www.viatris.com

Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - Specialty & Generic
Employés à temps plein: 38 000

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Scott Andrew Smith	CEO & Director	S.O.	S.O.	1962
Mr. Paul B. Campbell	Chief Accounting Officer, Senior VP & Corporate Controller	S.O.	S.O.	1968
Mr. Ramkumar V. Rayapureddy	Chief Information Officer	S.O.	S.O.	S.O.
Mr. Brian S. Roman	Chief Legal Officer	S.O.	S.O.	1971
Mr. Andrew Enrietti	Chief People Officer	S.O.	S.O.	S.O.
Mr. Menassie Taddese M.B.A.	President of Emerging Markets	S.O.	S.O.	1970
Mr. Derek Glover	Chief Quality Officer	S.O.	S.O.	S.O.
Ms. Lara Ramsburg	Chief Corporate Affairs Officer	S.O.	S.O.	S.O.
Dr. Jeffrey Nau MMS, Ph.D.	President of Viatris Eye Care Division	S.O.	S.O.	1976
Mr. Philippe Martin	Chief R&D Officer	S.O.	S.O.	1975

Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Viatris Inc. en date du 29 avril 2024 est 8. Les scores principaux sont Audit : 10; Société : 4; Droits des actionnaires : 8; Compensation : 6.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.